# DESCRIPTION

## STATEMENT OF FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

- disclose government support

## FIELD OF THE INVENTION

- define fields of invention

## BACKGROUND OF THE INVENTION

- introduce Klebsiella pneumoniae and Pseudomonas aeruginosa
- describe virulence factors of Klebsiella pneumoniae
- discuss limitations of capsule-based vaccines
- highlight importance of LPS as a vaccine target
- motivate OPS-based vaccine approach
- introduce COPS conjugate vaccines
- describe Pseudomonas aeruginosa flagella as virulence factors
- discuss flagellin-mediated protection against Pseudomonas aeruginosa infections
- highlight expression and purification of Pseudomonas aeruginosa flagellins
- summarize immune responses towards flagellins of various bacterial pathogens
- introduce need for broad spectrum vaccine against Klebsiella pneumoniae and Pseudomonas aeruginosa

## SUMMARY OF THE INVENTION

- introduce conjugate vaccine embodiments
- describe various vaccine compositions
- outline methods for preparation and administration

## DETAILED DESCRIPTION OF THE INVENTION

- introduce conjugate vaccine for Klebsiella and Pseudomonas bacterial infections

### Conjugate

- define conjugate composition
- describe Klebsiella surface polysaccharide antigen
- describe Pseudomonas flagellin protein or antigenic fragment or derivative

### Compositions

- define vaccine compositions
- describe conjugates of Pseudomonas flagellin and Klebsiella surface polysaccharides
- list embodiments of multivalent conjugate vaccines
- outline compositions with effective amounts of conjugates
- discuss pharmaceutical compositions with pharmaceutically acceptable carriers
- describe adjuvants and their use in compositions
- define vaccine composition
- formulate for administration routes
- describe parenteral administration
- describe oral administration
- describe pulmonary delivery
- describe kits and formulations

### Methods of Treatment

- define method of inducing immune response
- describe conjugate composition and administration
- outline immune response characteristics
- discuss immunogenicity measurement
- describe administration regimens and dosages
- outline prophylactic and therapeutic uses

### Methods of Making the Conjugate

- cite prior art for conjugate vaccine production
- describe method of binding Klebsiella surface polysaccharide antigen and Pseudomonas flagellin protein
- detail covalent binding of Pseudomonas aeruginosa flagellin type A and/or B to O polysaccharide
- describe isolation of surface polysaccharide antigen from Klebsiella pneumoniae serovar
- describe isolation of Pseudomonas flagellin protein from heterologous Gram-negative bacteria expression system
- outline methods for conjugating surface polysaccharide antigen and flagellin
- describe use of crosslinking agents and functional groups for conjugation
- discuss purification and processing of conjugate

### Genetically Engineered Strains

- describe modified Klebsiella strains
- specify attenuating mutations in Klebsiella
- introduce Gram-negative bacteria engineered to express Pseudomonas flagellin
- describe mutations in Gram-negative bacteria
- specify inactivating mutations in fliC
- describe attenuated strains with mutations in guaBA locus and clpPX locus
- explain mutations in guaA and guaB genes
- describe deletion mutants of clpP and clpX genes

## EXAMPLES

### Example 1

- develop scalable bioprocesses for flagellin and OPS purification
- conjugate OPS with flagellin using various methods
- test immunogenicity of Salmonella COPS:Flagellin conjugates in mice
- evaluate functional activity of vaccine-induced antibodies
- engineer bacteria for safe and economic purification of PA flagellin and OPS
- design research for KP and PA strains
- genetically engineer Klebsiella strains
- construct recombinant S. Enteritidis that express Type A and B flagella
- construct reagent strain S. Enteritidis CVD1947
- purify and characterize Klebsiella pneumoniae O1 O-polysaccharide
- express and purify Pseudomonas aeruginosa flagellin and conjugate with Klebsiella pneumoniae O1 OPS
- introduce conjugate vaccine approach
- motivate KP and PA antigens
- describe conjugate synthesis and characterization
- outline immunization and serological measurements
- describe construction of mouse virulent challenge strains
- prepare bacteria for functional antibody assays and challenge experiments
- describe opsonophagocytic assays
- outline proof-of-concept and down-selection of conjugate formulations
- assess quadrivalent conjugate formulation and therapeutic antibody preparations
- describe motility inhibition assays
- outline hyper-immunization of rabbits
- detail passive transfer immunization
- summarize mouse infection models
- outline statistical power calculations
- describe porcine wound model and expected results

